Long-term efficacy and tolerability of candesartan cilexetil in patients with mild to moderate hypertension

Journal of Human Hypertension

Volumn 11, Issue SUPPL. 2, 1997, Pages

  Sever, P ^a   Holzgreve, H ^b  

^a ST MARY S HOSPITAL   (United Kingdom)

^b UNIVERSITY OF MUNICH   (Germany)

Author keywords

Candesartan cilexetil; Efficacy tolerability; Essential hypertension; Long term study

Indexed keywords

CANDESARTAN HEXETIL;

ADULT; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; BACKACHE; BRONCHITIS; CLINICAL TRIAL; COMMON COLD; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DIASTOLIC BLOOD PRESSURE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; ESSENTIAL HYPERTENSION; FATIGUE; FEMALE; GASTROENTERITIS; HEADACHE; HUMAN; INFLUENZA; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; ORAL DRUG ADMINISTRATION; PHASE 3 CLINICAL TRIAL; SINGLE BLIND PROCEDURE; URINARY TRACT INFECTION; VERTIGO;

ADOLESCENT; ADULT; AGED; ANTIHYPERTENSIVE AGENTS; BENZIMIDAZOLES; BIPHENYL COMPOUNDS; FEMALE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RECEPTORS, ANGIOTENSIN; SINGLE-BLIND METHOD; TETRAZOLES;

EID: 0030699385     PISSN: 09509240     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (7)

1. Ashton WT. Nonpeptide angiotensin II receptor antagonists. Exp Opin Invest Drugs 1994; 3: 1105-1142.
2. Morimoto S, Ogihara T. TCV-116: a new angiotensin II type-I receptor antagonist. Cardiovasc Drug Rev 1994; 12: 153-164.
3. Nishikawa K et al. Pharmacological profile of a novel nonpeptide angiotensin II subtype 1 receptor antagonist, TCV-116. Blood Press 1994; 3 (Suppl 5): 7-14.
4. Shibouta Y et al. Pharmacological profile of a highly potent and long-acting angiotensin II receptor antagonist, 2-ethoxy-1-[[2′-(1H-tetrazol-5yl]biphenyl-4-yl]methyl]-1H-benzimidazole-7- carboxylic acid (CV-11974), and its prodrug, (±)-1-(cyclohexyloxy-carbonyloxy)-ethyl 2-ethoxy-1-[[2′-(1H-tetrazol-5yl] biphenyl-4-yl]methyl]-1H-benzimidazole-7-carboxylate (TCV-116). J Pharmacol Exp Ther 1993; 266: 114-120.
5. Delacretaz E et al. Characterization of the angiotensin II receptor antagonist TCV-116 in healthy volunteers. Hypertension 1995; 25: 14-21.
6. Ogihara T et al. Open clinical studies on a new angiotensin II receptor antagonist, TCV-116. J Hypertens 1994; 12 (Suppl 9): S35-S38.
7. Yoshinaga K et al. Efficacy, safety and usefulness of MK-954 (losartan potassium), angiotensin II receptor antagonist, on essential hypertension in the long-term treatment [in Japanese]. Rinsho-Iyaku 1995; 11: 175-207.